THE MODELING OF CLINICAL OUTCOMES IN PATIENTS WITH ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA OF THE UTERINE BODY
https://doi.org/10.51523/2708-6011.2016-13-4-25
Abstract
Objective: to create a mathematical model of prognosis of endometrial adenocarcinoma of the uterine body I-III stages. Material and methods. The training group included 60 patients, the screening one - 40. The clinical course of the disease in each female patient was monitored using data of the Belarusian Cancer Registry. Predictors that had a significant (p < 0.05) effect on the survival rate were selected by multivariable regression analysis of Cox`s proportional hazards. Results. Among all the studied morphological and immunohistochemical parameters of endometrioid adenocarcinoma only 4 were predictors of adverse clinical outcomes of the disease: vascular area, expression of CD3-lymphocytes, dendritic cells (S100), and the expression of vascular growth factor (VEGF). Conclusion. The results of this study give an opportunity to put the female patients into groups with high or low survival rate with the diagnostic accuracy of 92.5 %.
About the Authors
D. A. Zinovkin
Republican Research Center for Radiation Medicine and Human Ecology, Gomel
Belarus
Belarus
E. A. Nadyrov
Republican Research Center for Radiation Medicine and Human Ecology, Gomel
Belarus
Belarus
References
1. Early recurrence of early stage endometrioid endometrial carcinoma: possible etiologic pathways and management options / C. Iavazzo [et al.] // Maturitas. - 2014. - Vol. 78, № 3. - P. 155-159.
2. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade / R. Urabe [et al.] // J. Obstet. Gynaecol. Res. - 2014. - Vol. 40, № 3. - P. 812-819.
3. Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer / S. Tangjitgamol [et al.] // Histol. Histopathol. - 2013. - Vol. 28, № 6. - P. 787-794.
4. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008 / P. M. Jamison [et al.] // Cancer Epidemiol. Biomarkers Prev. - 2013. - Vol. 22, № 2. - P. 233-241.
5. Lymphadenectomy for the management of endometrial cancer / K. May [et al.] // Cochrane Database Syst. Rev. - 2010. - Vol. 20, № 1. - P. 75-85.
6. Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy / S. Owusu-Darko [et al.] // J. Reprod. Med. - 2014. - Vol. 59. - P. 527-533.
7. Stewart, C. J. Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion / C. J. Stewart, M. L. Crook // Int. J. Gynecol. Pathol. - 2010. - Vol. 29, № 6. - P. 555-561.
8. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma / E. Euscher [et al.] // Am J SurgPathol. - 2013. - Vol. 37, № 11. - P. 1728-1736.
9. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment / J. N. Barlin [et al.] // Int. J. Gynecol. Cancer. - 2013. - Vol. 23, № 9. - P. 1620-1628.
10. Shurin, M. R. The Tumor Immunoenvironment / M. R. Shurin, V. Umansky, A. Malyguine. - New York: Springer, 2013. - P. 19-125.
11. Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma / I. K. Jung [et al.] // Obstet. Gynecol. Sci. - 2014. - Vol. 57, № 4. - Р. 266-273.
12. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma / A. Honig [et al.] // Anticancer Res. - 2005. - Vol. 25, № 3A. - P. 1747-1753.
13. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma / Z. Lijun [et al.] // Int. J. Gynecol. Cancer. - 2012. - Vol. 22, № 5. - P. 836-841.
14. Schmid, B. C. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers / B. C. Schmid, M. K. Oehler // Curr. Treat. Options Oncol. - 2015. - Vol. 16, № 1. - P. 318.
15. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma / S. K. Saarelainen [et al.] // Tumour. Biol. - 2014. - Vol. 35, № 5. - P. 4651-4657.
Review
For citations:
Zinovkin D.A., Nadyrov E.A. THE MODELING OF CLINICAL OUTCOMES IN PATIENTS WITH ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA OF THE UTERINE BODY. Health and Ecology Issues. 2016;(4):114-118. (In Russ.) https://doi.org/10.51523/2708-6011.2016-13-4-25
Views: 272
Email this article 